2013
DOI: 10.1007/s00213-013-3232-4
|View full text |Cite
|
Sign up to set email alerts
|

The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders

Abstract: Rationale and Objectives Modafinil (MOD) and its R-enantiomer (R-MOD) are approved medications for narcolepsy and other sleep disorders. They have also been used, off label, as cognitive enhancers in populations of patients with mental disorders, including substance abusers that demonstrate impaired cognitive function. A debated non-medical use of MOD in healthy individuals to improve intellectual performance is raising questions about its potential abuse liability in this population. Results and Conclusions… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
100
1
1

Year Published

2014
2014
2022
2022

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 117 publications
(102 citation statements)
references
References 197 publications
(312 reference statements)
0
100
1
1
Order By: Relevance
“…Although this overall finding is similar to that found in the paper by Mazanov et al (2013), among their sample of modafinil users, only 49% of individuals reported using this substance exclusively for the purposes of study-related CE. This increase in use may be a consequence of recent research highlighting the lower abuse potential of modafinil in comparison to stimulant medications, such as methylphenidate and other mixedamphetamine salts (Mereu et al 2013, for review). It will be important to monitor whether this trend towards increasing use of modafinil continues in the future.…”
Section: Discussionmentioning
confidence: 99%
“…Although this overall finding is similar to that found in the paper by Mazanov et al (2013), among their sample of modafinil users, only 49% of individuals reported using this substance exclusively for the purposes of study-related CE. This increase in use may be a consequence of recent research highlighting the lower abuse potential of modafinil in comparison to stimulant medications, such as methylphenidate and other mixedamphetamine salts (Mereu et al 2013, for review). It will be important to monitor whether this trend towards increasing use of modafinil continues in the future.…”
Section: Discussionmentioning
confidence: 99%
“…As outlined above, that outcome is thought to be predictive of atypical effects, and indeed modafinil is reported to have low abuse liability (Minzenberg and Carter, 2008) and potential efficacy as a treatment for cocaine abuse (Hart et al, 2008; Dackis et al, O'Brien, 2012). Other studies directed at treatment of stimulant abusers have reported mixed results (see review by Mereu et al, 2013), although it is clear that modafinil does not produce a cocaine-like ‘high’ in humans and has little abuse liability of its own, even in frequent cocaine users (Vosburg et al, 2010). However, in contrast to the effects of other compounds promoting an inward-facing DAT conformation, modafinil fully substituted for cocaine in mice trained to discriminate cocaine (10 mg/kg) from saline injections (Loland et al 2012), stimulated locomotor activity, though to a lesser extent than cocaine (Cao et al, 2010), and increased DA concentrations in the nucleus accumbens shell, though also to a lesser extent than cocaine and with an apparent plateau across the doses below those producing acute toxicity (Loland et al, 2012).…”
Section: Effects Of Atypical Dat Inhibitorsmentioning
confidence: 99%
“…Modafinil is a drug approved for the pharmacological management of narcolepsy, and is currently used off-label to treat psychostimulant dependence with promising results (Mereu et al, 2013). Although it has stimulant-like effects in humans and animals, it has a complex pharmacology that is clearly different from those of the catecholaminergic stimulants like d-amphetamine and methylphenidate.…”
Section: Introductionmentioning
confidence: 99%
“…Despite the fact that modafinil has modest micromolar affinity for DAT (Madras et al, 2006; Zolkowska et al, 2009) and low affinity for norepinephrine or 5-hydroxytryptamine transporters (NET and SERT) (Madras et al, 2006; Minzenberg and Carter, 2008), positron emission tomography experiments in humans have revealed that therapeutic doses of modafinil occupy a substantial proportion of striatal DAT sites in human subjects and increase synaptic dopamine concentrations (Volkow et al, 2009). Compared to classical psychostimulants such as cocaine or amphetamine, the sites of action and the behavioral effects of modafinil appear to be different (Mereu et al, 2013). In addition, modafinil influences GABAergic, glutamatergic, noradrenergic, serotoninergic, histaminergic, and orexinergic systems (Mizenberg and Carter, 2008).…”
Section: Introductionmentioning
confidence: 99%